Article

FDA panel expresses concern over OTC OAB patch

Merck has confirmed that the FDA Nonprescription Drug Advisory Committee proposed that the FDA consider labeling modifications as part of its review of oxybutynin transdermal system (Oxytrol) as an over-the-counter treatment for overactive bladder in women.

Related Videos
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Jeffrey A. Albaugh, PhD, APRN, CUCNS, answers a question during a Zoom video interview
Amy M. Pearlman, MD, interviews Gia Ching on Zoom
Related Content
EU approves Mona Lisa 2.0 robotic system for prostate cancer
January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
FDA grants 510(k) clearance to RELIEF stent for vesicoureteral reflux
January 14th 2025

FDA grants 510(k) clearance to RELIEF stent for vesicoureteral reflux

Hannah Clarke
In a recent study of the RELIEF stent, 95% of patients showed no VUR following stent placement.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer
January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke
The PDUFA target action date has been set for August 29, 2025.
Enrollment goal met in trial of Urocross Expander Implant for BPH-related LUTS
January 13th 2025

Enrollment goal met in trial of Urocross Expander Implant for BPH-related LUTS

Hannah Clarke
The Expander-2 trial is intended to provide data that will support submission of the device for regulatory approval.
© 2025 MJH Life Sciences

All rights reserved.